Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 25,931 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07. Following the transaction, the chief financial officer now directly owns 109,665 shares in the company, valued at approximately $18,091,435.05. This represents a 19.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71.

Natera Stock Performance

NASDAQ:NTRA traded up $4.47 during midday trading on Wednesday, reaching $171.93. 2,052,001 shares of the company traded hands, compared to its average volume of 1,460,392. Natera, Inc. has a twelve month low of $62.96 and a twelve month high of $183.00. The firm has a market capitalization of $22.70 billion, a price-to-earnings ratio of -97.69 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a fifty day moving average price of $165.35 and a 200 day moving average price of $135.41.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.95) EPS. On average, analysts expect that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently modified their holdings of NTRA. Covestor Ltd lifted its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC increased its position in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the period. Hanseatic Management Services Inc. raised its holdings in Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock valued at $158,000 after acquiring an additional 107 shares in the last quarter. Finally, Salem Investment Counselors Inc. boosted its stake in Natera by 0.7% in the 4th quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company’s stock valued at $2,577,000 after buying an additional 110 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several research analyst reports. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Piper Sandler upped their price objective on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Craig Hallum raised their price target on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. TD Cowen boosted their price objective on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Guggenheim lifted their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $160.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.